The limited effect of omega-3 polyunsaturated fatty acids on cardiovascular risk in patients with impaired glucose metabolism: A meta-analysis

Clinical Biochemistry

Volumn 47, Issue 6, 2014, Pages 369-377

  Zheng, Tengfei ^a   Zhao, Jing ^a   Wang, Yushu ^a   Liu, Wennan ^b   Wang, Zhihao ^a   Shang, Yuanyuan ^a   Zhang, Wei ^a   Zhang, Yun ^a   Zhong, Ming ^a  

^a SHANDONG UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Cardiovascular risk markers; Docosahexaenoic acid; Eicosapentaenoic acid; Impaired glucose metabolism; Omega 3 polyunsaturated fatty acids

Indexed keywords

CHOLESTEROL; DOCOSAHEXAENOIC ACID; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; PLACEBO; TRIACYLGLYCEROL; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; LIPID;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; DIETARY INTAKE; DISORDERS OF CARBOHYDRATE METABOLISM; GLUCOSE BLOOD LEVEL; HEART RATE; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BLOOD PRESSURE; DIET RESTRICTION; DRUG EFFECTS; GENETIC HETEROGENEITY; METABOLISM; PATHOPHYSIOLOGY; PUBLISHING; RISK FACTOR; TREATMENT OUTCOME; VASODILATATION;

BIOMARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; FASTING; FATTY ACIDS, OMEGA-3; GENETIC HETEROGENEITY; GLUCOSE; HEART RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPIDS; PUBLICATION BIAS; RISK FACTORS; TREATMENT OUTCOME; VASODILATION;

EID: 84897111952     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.11.025     Document Type: Article

References (41)

1. GISSI-Prevenzione Investigators Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999, 354(9177):447-455.
2. Yokoyama M., Origasa H., Matsuzaki M., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007, 369(9567):1090-1098.
3. Kromhout D., Giltay E.J., Geleijnse J.M. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010, 363(21):2015-2026.
4. Galan P., Kesse-Guyot E., Czernichow S., Briancon S., Blacher J., Hercberg S. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ 2010, 29(341).
5. Rauch B., Schiele R., Schneider S., et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010, 122(21):2152-2159.
6. Kwak S.M., Myung S.K., Lee Y.J., Seo H.G. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med 2012, 172(9):686-694.
7. Rizos E.C., Ntzani E.E., Bika E., Kostapanos M.S., Elisaf M.S. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012, 308(10):1024-1033.
8. Marchioli R., Marfisi R.M., Borrelli G., et al. Efficacy of n-3 polyunsaturated fatty acids according to clinical characteristics of patients with recent myocardial infarction: insights from the GISSI-Prevenzione trial. J Cardiovasc Med (Hagerstown) Sep 2007, 8(Suppl. 1):S34-S37.
9. Oikawa S., Yokoyama M., Origasa H., et al. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2009, 2:535-539.
10. Marchioli R., Levantesi G., Silletta M.G., et al. Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial. Expert Rev Cardiovasc Ther 2009, 7(7):735-748.
11. Hu F.B., Cho E., Rexrode K.M., Albert C.M., Manson J.E. Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women. Circulation 2003, 107(14):1852-1857.
12. Erkkila A.T., Lichtenstein A.H., Mozaffarian D., Herrington D.M. Fish intake is associated with a reduced progression of coronary artery atherosclerosis in postmenopausal women with coronary artery disease. Am J Clin Nutr 2004, 80(3):626-632.
13. Bosch J., Gerstein H.C., Dagenais G.R., et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012, 367(4):309-318.
14. Tramer M.R., Reynolds D.J., Moore R.A., McQuay H.J. Impact of covert duplicate publication on meta-analysis: a case study. BMJ 1997, 315(7109):635-640.
15. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50(4):1088-1101.
16. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(7109):629-634.
17. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17(1):1-12.
18. Hendra T.J., Britton M.E., Roper D.R., et al. Effects of fish oil supplements in NIDDM subjects. Controlled study. Diabetes Care 1990, 8:821-829.
19. Morgan W.A., Raskin P., Rosenstock J. A comparison of fish oil or corn oil supplements in hyperlipidemic subjects with NIDDM. Diabetes Care 1995, 1:83-86.
20. McGrath L.T., Brennan G.M., Donnelly J.P., Johnston G.D., Hayes J.R., McVeigh G.E. Effect of dietary fish oil supplementation on peroxidation of serum lipids in patients with non-insulin dependent diabetes mellitus. Atherosclerosis 1996, 2:275-283.
21. Sirtori C.R., Paoletti R., Mancini M., et al. n-3 fatty acids do not lead to an increased diabetic risk in patients with hyperlipidemia and abnormal glucose tolerance. Italian Fish Oil Multicenter Study. Am J Clin Nutr 1997, 6:1874-1881.
22. Luo J., Rizkalla S.W., Vidal H., et al. Moderate intake of n-3 fatty acids for 2months has no detrimental effect on glucose metabolism and could ameliorate the lipid profile in type 2 diabetic men. Results of a controlled study. Diabetes Care 1998, 5:717-724.
23. Petersen M., Pedersen H., Major-Pedersen A., Jensen T., Marckmann P. Effect of fish oil versus corn oil supplementation on LDL and HDL subclasses in type 2 diabetic patients. Diabetes Care 2002, 10:1704-1708.
24. Woodman R.J., Mori T.A., Burke V., Puddey I.B., Watts G.F., Beilin L.J. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr 2002, 5:1007-1015.
25. Mostad I.L., Bjerve K.S., Bjorgaas M.R., Lydersen S., Grill V. Effects of n-3 fatty acids in subjects with type 2 diabetes: reduction of insulin sensitivity and time-dependent alteration from carbohydrate to fat oxidation. Am J Clin Nutr 2006, 3:540-550.
26. Kabir M., Skurnik G., Naour N., et al. Treatment for 2mo with n-3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study. Am J Clin Nutr 2007, 86(6):1670-1679.
27. Holman R.R., Paul S., Farmer A., Tucker L., Stratton I.M., Neil H.A. Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial. Diabetologia 2009, 1:50-59.
28. Pooya S., Jalali M.D., Jazayery A.D., Saedisomeolia A., Eshraghian M.R., Toorang F. The efficacy of omega-3 fatty acid supplementation on plasma homocysteine and malondialdehyde levels of type 2 diabetic patients. Nutr Metab Cardiovasc Dis 2010, 5:326-331.
29. Stirban A., Nandrean S., Götting C., et al. Effects of n-3 fatty acids on macro- and microvascular function in subjects with type 2 diabetes mellitus. Am J Clin Nutr 2010, 3:808-813.
30. Wong C.Y., Yiu K.H., Li S.W., et al. Fish-oil supplement has neutral effects on vascular and metabolic function but improves renal function in patients with type 2 diabetes mellitus. Diabet Med 2010, 1:54-60.
31. Kromhout D., Geleijnse J.M., Goede J., et al. n-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in postmyocardial infarction patients with diabetes. Diabetes Care 2011, 12:2515-2520.
32. Westerveld H.T., Graaf J.C., Breugel H.H., et al. Effects of low-dose EPA-E on glycemic control, lipid profile, lipoprotein(a), platelet aggregation, viscosity, and platelet and vessel wall interaction in NIDDM. Diabetes Care 1993, 5:683-688.
33. Axelrod L., Camuso J., Williams E., Kleinman K., Briones E., Schoenfeld D. Effects of a small quantity of omega-3 fatty acids on cardiovascular risk factors in NIDDM. A randomized, prospective, double-blind, controlled study. Diabetes Care 1994, 1:37-44.
34. Roncaglioni M.C., Avanzini F., Barlera S., et al. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med 2013, 368(19):1800-1808.
35. McVeigh G.E., Brennan G.M., Cohn J.N., Finkelstein S.M., Hayes R.J., Johnston G.D. Fish oil improves arterial compliance in non-insulin-dependent diabetes mellitus. Arterioscler Thromb 1994, 9:1425-1429.
36. Deeks J.J., Altman D.G. Effect measures for meta-analysis of trials with binary outcomes. Systematic reviews in health care 2008, 313-335. BMJ Publishing Group.
37. Simopoulos A.P. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother 2002, 56:365-379.
38. Neaton J.D., Blackburn H., Jacobs D., et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992, 152(7):1490-1500.
39. McVeigh G.E., Brennan G.M., Johnston G.D., et al. Dietary fish oil augments nitric oxide production or release in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1993, 1:33-38.
40. Sirtori C.R., Crepaldi G., Manzato E., et al. One-year treatment with ethyl esters of n-3 fatty acids in patients with hypertriglyceridemia and glucose intolerance: reduced triglyceridemia, total cholesterol and increased HDL-C without glycemic alterations. Atherosclerosis 1998, 2:419-427.
41. Mostad I.L., Bjerve K.S., Lydersen S., Grill V. Effects of marine n-3 fatty acid supplementation on lipoprotein subclasses measured by nuclear magnetic resonance in subjects with type II diabetes. Eur J Clin Nutr 2008, 3:419-429.